Drug-induced vascular injury (DIVI), defined as arterial medial degeneration/necrosis usually associated with perivascular inflammation, is frequently observed in the mesenteric arteries of rats but the relevance to humans remains a hurdle for drug development. Here, we describe the evaluation of commercially available optical imaging biomarkers using a rat DIVI model. Male Sprague Dawley rats were administered 10 mg/kg/day of a proprietary soluble guanylate cyclase activator (sGCa). Optical agents, AngioSense for the detection of vessel permeability, MMPSense for the detection of activated matrix metalloproteinases (MMPs), and IntegriSense for the detection of a v b 3 integrin, were injected via tail vein 24 hours before fluorescence (FL) ex vivo imaging.
D rug-induced vascular injury (DIVI) can be a hurdle in the development of new therapeutics. DIVI is believed to result from variations in blood pressure (vasoactive compounds) and subsequent mechanical damage to the vessel walls, or result from chemical interactions of therapeutics with the cells and extracellular matrix (ECM) of the vessels and surrounding tissues. [1] [2] [3] [4] [5] [6] [7] [8] Both models of vessel injury may progress into changes in vascular integrity, remodeling, and inflammation associated with the hyperplasia of vascular smooth muscle cells (VSMC) and changes in the ECM. 1, 2, 9 Matrix metalloproteinases (MMPs) 1, 2, 10 have key regulatory functions in tissue remodeling associated with cellcell and cell-matrix interactions in vascular pathology. For instance, MMP-2, -3, and -9 have been implicated as the primary MMPs contributing to the development of vulnerable plaques in atherosclerotic vessel lesions, 2, 11 and the upregulation of MMP-3 has been identified in the serum of patients with antineutrophil cytoplasmic antibodyassociated vasculitis. 12 MMPs in vascular remodeling are released by inflammatory cells, macrophages, foam cells, and VSMC. [13] [14] [15] Contributions of individual MMPs to development and progression of vascular remodeling have not yet been fully elucidated. The upregulation of MMP-2 has been associated with response to mechanical injury and the stretching of vessel walls, whereas inflammatory cytokines induce expression of a broad range of MMPs, including MMP-1, -3, and -9. [16] [17] [18] [19] [20] [21] VSMC proliferation and migration in vascular remodeling is supported by the upregulation of integrins such as a v b 3 .
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In the rat, the evaluation of DIVI has been traditionally performed by the histopathological examination of the mesenteric arteries. This technique is time consuming, with limited quantification, and requires high numbers of animals. In addition, to assess and visualize changes in vascular integrity, remodeling, and inflammation associated with DIVI, development of targeted imaging tools that reveal this common physiologic response to vascular injury regardless of the initiating insult would be valuable.
Here we evaluated three commercially available optical imaging agents: AngioSense, IntegriSense, and MMPSense. AngioSense, a blood pool agent used in oncology for the detection of vessel permeability, was used in our experiments to investigate detection of biomechanical vessel damage as a result of DIVI. IntegriSense, a selective ligand of a v b 3 integrin used in the detection of angiogenesis during vascular remodeling, was evaluated for the detection of upregulation of a v b 3 integrin as a result of VSMC proliferation and translation. Lastly, since MMPs are central to vascular remodeling, DIVI-associated MMP activity was measured using the MMPSense reporter. Rats were treated with a proprietary soluble guanylate cyclase activator (sGCa). sGCas are well studied vasodilators that act through the nitric oxidesoluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway 6, 26, 27 to cause substantial decreases in blood pressure and reflex tachycardia. It has been documented through internal and published studies that high concentrations of sGCas cause DIVI in the mesenteric arteries of rats. 28 The optical agents were used to quantitatively measure DIVI in rat mesenteric arteries after oral dosing of the sGCa, and concordance was assessed with histopathology and immunohistochemistry.
Methods

Study Design
To evaluate the utility of the imaging agents in detecting DIVI, groups (n 5 6) of male Sprague Dawley (SD) rats (8 weeks old, 150 to 250 g, total 72 rats) (Charles River Laboratories, Raleigh, NC) received 10 mg/kg/day of the proprietary sGCa or vehicle (100% polyethylene glycol [PEG] 400) by oral gavage for 2 or 4 days. Rats were injected with AngioSense 750EX (10 nmol in 100 mL), MMPSense 750 FAST (20 nmol in 200 mL), or IntegriSense 750 (20 nmol in 200 mL) (all from Perkin Elmer, Waltham, MA) via tail vein 24 hours before imaging. On the day of imaging, the rats were euthanized with CO 2 and their mesenteric arteries were excised. Images were acquired using the IVIS Spectrum imaging system (Perkin Elmer).
To evaluate the agents' sensitivity over a broader dose range of sGCa, groups (n 5 6) of male SD rats were administered 10, 3, 1, 0.3, or 0.1 mg/kg/day of the sGCa or vehicle for 2 days (AngioSense 750EX) or 4 days (MMPSense 750 FAST). Rats were injected with AngioSense 750EX or MMPSense 750 FAST via tail vein 24 hours before imaging. On the day of imaging, the rats were euthanized with CO 2 and their mesenteric arteries were excised; images were acquired as noted above.
For the double-reporter study, groups (n 5 6) of male SD rats (8 weeks old, total 18 rats) were administered 1 mg/kg/day or 10 mg/kg/day of sGCa or vehicle for 2 days. Rats were injected with both AngioSense 680EX and MMPSense 750 FAST simultaneously (all from Perkin Elmer) via tail vein 24 hours before imaging. On the day of imaging, the rats were euthanized with CO 2 and their mesenteric arteries were excised and imaged.
All animal husbandry and experimental procedures were in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication 25, No. 28, 16 August 1996) and were approved by the Institutional Animal Care and Use Committee.
In Vitro Fluorescence Assay for Dual-reporter Study
In order to evaluate the overlap of the fluorescence (FL) of AngioSense 680EX and activated MMPSense 750 FAST, we carried out measurements of the imaging biomarkers in a 96-well plate. Into one well of a 96-well black plate with 100 pmol (in 1 mL) of AngioSense 680EX or MMPSense 750 FAST, we mixed 49 mL of phosphate buffered saline (PBS) and 50 mL of dimethyl sulfoxide. The plate was then imaged with two filter sets (excitation [ex] wavelength: 745 nm, emission [em] wavelength: 800 nm; or ex: 675 nm, em: 720 nm) using the IVIS Spectrum.
Flow Cytometry
After agent-injected (MMPSense 750 FAST) rats were euthanized, their mesenteric arteries were excised. The arteries were minced with fine scissors and dissociated into single cells by incubating with Liberase TH and TM (Roche Applied Science, Indianapolis, IN) at 37uC for 1.5 hours with intermittent mixing. The resulting cell suspensions were then passed through a 40 mm cell strainer (BD Biosciences, Bedford, MA) and washed with PBS. All samples were incubated in ammonium-chloride-potassium (ACK) buffer (Cambrex, Walkersville, MD) to remove blood cells and then washed with PBS. For multicolor flow cytometry analysis of lymphoid cells, myeloid cells (including monocytes/macrophages and neutrophils), and other cells (including stromal cells of the arterial wall), cells were incubated with a cocktail of monoclonal antibodies (all from BD Biosciences) against T cells (CD3-FITC), B cells (CD45RA-FITC), NK cells (CD161a-FITC), and myeloid cells (CD11b-PE) at 4uC for 30 minutes and analyzed by flow cytometer (LSR II, BD Biosciences). Acquisition data was analyzed by the FlowJo software (Tree Star Inc., Ashland, OR).
Ex Vivo Optical Imaging and Data Analysis
IVIS Spectrum
Mesenteric arteries were imaged with an excitation filter of 745 nm and an emission filter of 800 nm for animals injected with AngioSense 750EX, MMPSense 750 FAST, or IntegriSense 750. For animals injected with AngioSense 680EX, arteries were imaged with an excitation filter of 675 nm and an emission filter of 720 nm. Exposure time was automatically determined by the instrument to exceed 10,000 counts. One region of interest (ROI) was manually drawn to include the complete mesenteric arteries by using the vendor's software (Living Image 4.0, Perkin Elmer) for each image. Average radiance (p/s/cm 2 /sr) was then calculated by the software for each ROI.
Immunohistochemistry
After the arteries were imaged, they were fixed in 10% buffered formalin, processed to paraffin blocks, sectioned at 4 mm, and placed onto adhesive-coated slides. The slides were immunostained using a rabbit anti-MMP9 polyclonal antibody (ab38898; Abcam, Cambridge, MA). Briefly, sections were deparaffinized and hydrated to PBS. Endogenous peroxidases were blocked with H 2 O 2 treatment. Sections were incubated with the optimal concentration of rabbit polyclonal anti-MMP-9 immunoglobulin (IgG) for 1 hour at room temperature. After washes in PBS, sections were incubated with a horseradish peroxidase-conjugated anti-rabbit IgG polymer, followed by development with 3,3'-diaminobenzidine chromogen and finally counterstaining with hematoxylin. Replicate sections were stained with hematoxylin and eosin to demonstrate general morphology.
Statistics
Data is presented as mean 6 SEM in the bar graph. For statistical analysis, we used the t-test for two group comparison. Differences were considered significant at p , .05.
Results
Identification of Optical Imaging Biomarkers for the Detection of Vascular Injury in Rat Mesenteric Arteries
To identify optical imaging biomarkers of DIVI, we used the sGCa-induced rat DIVI model. FL imaging found a statistically significant difference in the FL intensity of AngioSense ( Figure 1A ), MMPSense ( Figure 1B) , and IntegriSense ( Figure 1C ) between treated and vehicle groups for both 2-day and 4-day treatments (p , .05).
FL intensity of AngioSense in the mesenteric arteries of treated animals was approximately 3.2-fold (2-day treatment) and four-fold (4-day treatment) greater than the FL Figure 1 . Results of fluorescence imaging of rat mesenteric arteries dissected from vehicle-and sGCa-treated animals (10 mg/kg/day) that were injected with optical reporters. A, AngioSense 750. B, MMPSense 750 FAST. C, IntegriSense 750. Bar graphs in A, B, and C summarize the results for six animals in each cohort. Avg 5 average. intensity in the mesenteric arteries of vehicle group (see Figure 1A ). When using MMPSense, FL intensity of treated animals was around 3.6-fold (2-day treatment) and 4.3fold (4-day treatment) greater than the FL intensity of vehicle group (see Figure 1B) . IntegriSense, the highly selective ligand of a v b 3 integrin, detected elevated levels of integrin expression in mesenteric arteries of treated animals when compared with vehicle group (see Figure 1C ). FL intensity of treated animals was around 1.5-fold (2-day treatment) and 2.3-fold (4-day treatment) greater than the FL intensity of the vehicle group. Thus, although Integri-Sense detects the change in expression of the a v b 3 integrin between treated and vehicle arteries, the relative increase was the lowest of all the imaging biomarkers tested. For that reason, we have not further evaluated the sensitivity of this biomarker.
The postmortem histopathology analysis (one representative report is shown in Table 1 ) indicated medial degeneration and perivascular inflammation only in the mesenteric arteries of all treated animals (10 mg/kg/day) but not in the vehicle group (both 2-day and 4-day treatments), which is in agreement with the FL imaging results.
MMPSense and AngioSense Detection of Dosedependent DIVI
To evaluate the sensitivity of the two optical imaging biomarkers with the higher increase in FL, we carried out the experiments using a broad range of doses of sGCa. When using either MMPSense (Figure 2A) or AngioSense ( Figure 2B ) as a biomarker, there was a statistically significant difference between treated and vehicle groups at doses of 0.3, 1, and 10 mg/kg/day. Only one animal survived through the course of treatment in the 3 mg/kg/day group due to unexplained higher mortality (see Figure 2A ).
Simultaneous Detection of MMP Activity and Arterial Medial Damage/Permeability in Rat Mesenteric Arteries
To evaluate the potential association of MMP activity and arterial medial damage/permeability at the same time and from the same animals, we first performed an in vitro assay for AngioSense 680EX (ex: 675 nm, em: 720 nm) and MMPSense 750 FAST (ex: 745 nm, em: 800 nm) using the two filter sets indicated above, and determined how much signal of each probe could be detected when using the other filter set ( Figure 3 ). We found that only 1.97% of the AngioSense 680EX signal and 0.78% of the MMPSense 750 FAST signal could be detected when using the 745/800 nm (ex/em) and 675/720 nm (ex/em) filter sets, respectively. With this information, we conducted the dual-probe study with 18 animals (n 5 6/group). FL imaging demonstrated a statistically significant difference in the fluorescent signals from AngioSense 680EX and MMPSense 750 FAST between treated (both 1 mg/kg/day and 10 mg/kg/day) and vehicle groups after two days of treatment (p , .05) ( Figure 4 ).
Cellular Target Profile by Flow Cytometry
To analyze the cellular source of the FL ex vivo MMPSense signal, we performed flow cytometry of single cell suspensions generated from digested rat mesenteric arteries. Myeloid cells (monocytes/macrophages and neutrophils) were identified as one of the dominant cellular signal sources for MMPSense. The FL signal from MMPSense was also found in lymphoid cells and in other unspecified cells from the arteries, but the intensity was much lower. After treatment, the number and mean FL intensity of myeloid cells increased about two-fold. (Figure 5 , Table 2 ).
Immunohistochemical Analysis Reveals Higher MMP-9 Expression in Rat Mesenteric Arteries of Treated Animals
MMPSense can be activated by several MMPs, but mostly by MMP-9 and MMP-13. 27 In order to confirm the presence of MMPs for the activation of MMPSense, immunohistochemical analysis of MMP-9 expression was performed on rat mesenteric arteries of both control and treated (10 mg/kg/day of the sGCa) animals. After treatment, blood cell infiltration and perivascular inflammation were observed on hematoxylin and eosin stained slides. Higher MMP-9 expression was also observed in and around the medial layer of the mesenteric arteries from all treated animals ( Figure 6 ). 
Discussion
Drug-induced vascular injury is characterized by medial necrosis and hemorrhage, with perivascular acute inflammation associated with infiltration by inflammatory cells including macrophages, neutrophils, eosinophils, and lymphocytes. [2] [3] [4] The arterial tissue remodeling following vascular injury is accompanied by the activation of several MMPs (such as MMP-9, MMP-2, MMP-3, and MMP-13) involved in vascular smooth muscle cell activation and neointima formation. 3, 5 Current histopathology methods for assessing DIVI are laborious and only semiquantitative at best. The development of imaging biomarkers could provide a more quantitative dataset and dramatically decrease the time and resources needed to acquire such data. sGCas are well studied vasodilators that act through the NO-sGC-cGMP signaling pathway 6, 26, 27 to cause substantial decreases in blood pressure and reflex tachycardia. It has been documented through internal and published studies that high concentrations of sGCa cause DIVI in the mesenteric arteries of rats. 28 Thus, we used a proprietary sGCa that in internal studies caused highly reproducible vascular injury in the mesenteric arteries, in the optical imaging studies.
To identify an optical imaging biomarker for the detection of DIVI, we hypothesized that mechanical arterial medial damage could be monitored by AngioSense, that upregulated activated MMPs could be monitored by MMPSense, and that the expression of a v b 3 integrin associated with inflammation/angiogenesis could be monitored by IntegriSense. The blood pool agent, AngioSense, has previously been used to assess the leakiness and permeability of blood vessels within tumors, 29 whereas the Optical Imaging of Vascular Injury MMP activation reporter, MMPSense, and the a v b 3 integrin reporter, IntegriSense, have been used to assess inflammation associated with atherosclerosis. 30, 31 We have demonstrated that there is a statistically significant difference in the FL intensity of all three imaging biomarkers tested between the treated and vehicle groups for both 2-day and 4-day treatments (p , .05). Our results show that AngioSense and MMPSense are more sensitive biomarkers than IntegriSense at 10 mg/kg/day of sGCa. Therefore, we did not study the sensitivity of IntegriSense further. In addition, we have demonstrated that visualization of MMP activation through MMPSense and increased vessel permeability through AngioSense in the mesentery of treated rats correlated well with DIVI histopathological findings. Experiments that assessed the effects of the sGCa dose response on both DIVI and optical imaging biomarker staining demonstrated that the amount of FL intensity with either MMPSense or AngioSense correlated with the degree of DIVI. IntegriSense was less sensitive than the other biomarkers and showed strong time dependence and animal variability, and thus did not provide a required experimental window for the design of a reliable screening assay. To obtain information on both MMP activity (MMPSense) and arterial medial damage/permeability (AngioSense) at the same time and from the same animals, we performed a double-reporter study. We found that the intensity of AngioSense 750EX is higher than MMPSense 750 FAST in rat mesenteric arteries (see Figure 1 and Figure 2 ), which would result in the overlap of the FL signal when used at the same time. The extinction coefficient of AngioSense 680EX is low at 745 nm and the extinction coefficient of MMPSense 750 at 680 nm is also very low as confirmed by about 100-fold lower FL of both agents when these wavelengths are used for excitation (see Figure 3 ). Since the signal overlap of both probes was minimal when excited at 680 and 750 nm, we confirmed that the doublereporter study demonstrated a parallel increase in the accumulation of the blood pool agent and activation of the MMP agent at the same time. Thus, the molecular processes detected by the MMP agent appear to be associated with the mechanical damage of the arterial walls and surrounding tissue as detected by the AngioSense reporter.
Flow cytometry of the digested tissue proved to be a useful tool to examine the cellular source of the FL signal. 26, 31 In this study, we evaluated the cellular FL source of MMPSense, since MMPs are expressed within cells and can be analyzed using flow cytometry whereas AngioSense is most likely distributed within the extracellular space of the vessel wall and is washed off during the tissue digestion process. After treatment, the number of myeloid cells increased, which indicated perivascular acute inflammatory cell infiltration. Furthermore, the mean FL intensity of MMPSense per cell in all cell types tested increased, and the myeloid cells were identified as one of the dominant cellular signal sources for MMPSense. Immunohistochemistry identified elevated levels of MMP-9 in the arterial walls and surrounding tissue, in agreement with the elevated levels of MMPSense fluorescent signal in the tissues collected from rats treated with sGCa.
In a separate study (unpublished data), we used the imaging biomarkers identified here, MMPSense and AngioSense, for fenoldopam induced vascular injury rat model. Fenoldopam is a dopaminergic vasodilator that has been shown in literature to cause vascular injury in rats. We have also detected significantly higher signal from both probes in treated animals compared to vehicle group. To the best of our knowledge, this is the first demonstration of molecular imaging biomarkers for DIVI. The applications of these biomarkers, together with the high throughput of optical imaging, provide a powerful screening assay for the preclinical evaluation of new therapeutics for potential DIVI. There are blood pool contrast agents for MRI that may be useful for detecting hemorrhage and could enable translation. Identification of MMPs as a key contributor to vascular injury opens new areas for the development of an assay using radioactive tracers based on MMP inhibitors and positron emission tomography or single-photon emission computed tomography imaging techniques, which would enable clinical translation.
